What question did this study set out to answer?

To evaluate the institutional characteristics and operating features of health technology assessment (HTA) systems across 32 countries and examine how these variations influence healthcare funding and coverage decisions.

November 29, 2021PharmacoEconomics - OpenOpen Access

Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries

View Full Paper

Ask AI

Bookmark

To evaluate the institutional characteristics and operating features of health technology assessment (HTA) systems across 32 countries and examine how these variations influence healthcare funding and coverage decisions.
Developed a conceptual framework based on a literature review to map HTA activities across 32 countries (European Union member states, the UK, Canada, and Australia).
Collected organizational data through systematic searches of competent authority websites and grey literature sources.
Conducted primary expert consultations to validate findings and cross-check institutional frameworks.
Identified 63 HTA bodies, of which 76% maintain a national scope, 73% operate independently, 52% hold an advisory role, and 76% predominantly or exclusively evaluate pharmaceuticals.
Assessed technologies based on both clinical and cost-effectiveness in 73% of agencies, with 94% incorporating committee-level stakeholder participation and 76% using external consultations.
Determined that recommendations from 81% of HTA bodies are not legally binding, resulting in substantial cross-country heterogeneity in how assessments translate into pricing, negotiation, and coverage decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative policy analysis reveals wide structural variation among 63 health technology assessment bodies across 32 countries, highlighting fragmented approaches to drug coverage decisions.

Cite This Study

Fontrier et al. (2021) studied this question.

synapsesocial.com/papers/6a980d71a2c7923eae15eecf https://doi.org/10.1007/s41669-021-00311-5

View Full Paper

Ask AI

Bookmark

Implication

Comparative policy analysis reveals wide structural variation among 63 health technology assessment bodies across 32 countries, highlighting fragmented approaches to drug coverage decisions.

Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries

Key Points

Discussion

Implication

Cite This Study

Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider